A More Disciplined Teva Gets Lukewarm Reception From Street
More organizational and strategic discipline, far greater selectivity in R&D and business development, and emphasis on profitable, not top-line, growth are at the core of the strategy put forth by Teva’s new management on Dec. 11. The reboot makes sense, given the company’s relentless focus on M&A over the past decade and its maturing generics businesses, so why are investors balking?
You may also be interested in...
Teva In Transition: Generics, Specialty And ‘The Space Between’
In an interview, President of Global R&D Michael Hayden talked about integrating Allergan generics, Teva’s late-stage specialty pipeline and its 17 new therapeutic entities, medicines that bridge generics and specialty medicine.
EMA Fells Two Orphan Drugs, Delays Teva’s Nerventra
The CHMP rejects AB Science’s Masiviera for pancreatic cancer, PTC Therapeutics’ Translarna for Duchenne muscular dystrophy and Teva’s Nerventra for MS.
Teva Struggles To Sell 2014 Guidance, Blue-Sky Estimates For NTE Program
The Israeli generics giant unveiled two sets of 2014 guidance, allowing for different levels of competition for Copaxone. But Wall Street sees the company slowing the pace of cost-cutting and providing overly optimistic revenue estimates for new therapeutic entities.